Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company focused on developing and commercializing targeted treatments for cancer using its proprietary technology platform. Based in New York, the company was founded in 2000 and focuses its operations on precision cancer medicine that seeks to leverage the body's own immune system to fight malignant cells.
Actinium's innovative Radiolabeled Antibody Technology employs Antibody Radiation Conjugates (ARCs), which allow for targeted delivery of a radioactive isotope, Actinium-225, directly to cancer cells, delivering the cell-killing power of radiation without the widespread damage to healthy tissue associated with standard radiation treatments. This precision approach potentially results in better efficacy, fewer side effects, and improved patient outcomes.
The company’s product line includes Iomab-B and Actimab-A. Iomab-B is an experimental treatment used in Bone Marrow Transplant (BMT), while Actimab-A is used in the treatment of Acute Myeloid Leukemia (AML).
Actinium Pharmaceuticals is actively involved in several ongoing clinical trials for both of these products and has a robust research and development pipeline, with several other therapeutic candidates in various stages of development aimed at solid and blood borne cancers.
The company also partners with other pharmacological and research institutions to continue to innovate and move the field of targeted cancer therapy forward. Actinium Pharmaceuticals, Inc. collaborates with world renowned cancer centers such as the Fred Hutchinson Cancer Research Center and the Memorial Sloan Kettering Cancer Center, underscoring its commitment to pursuing partnerships with leaders in the healthcare and pharmaceutical industry.
Actinium Pharmaceuticals, Inc. is publicly traded on the New York Stock Exchange under the ticker symbol "ATNM". The company has a dedicated team of professionals led by senior executives with extensive experience in the pharma and biotech industries.
In conclusion, Actinium Pharmaceuticals, Inc. is a key player in the emergent field of targeted cancer therapy. With their impressive portfolio of innovative products and ongoing research and development, they represent a beacon of hope for countless patients battling various forms of cancer.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Actinium Pharmaceuticals Inc. (NYSE: ATNM) saw its stock jump nearly 9% on Tuesday after announcing positive initial clinical results from its first-in-human Phase 1 study of ATNM-400 for metastatic castration-resistant prostate cancer (mCRPC). The findings, presented at a European conference, showed a favorable early safety profile and sustained tumor retention, leading to unusually heavy trading activity. The trial is evaluating a HER3-directed alpha radiotherapy and has cleared its initial dose level with no significant adverse events reported.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced that clinical and preclinical data for its investigational targeted radiotherapy, ATNM-400, will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM). The presentations will cover early Phase 1 data for ATNM-400 in metastatic castration-resistant prostate cancer and preclinical studies in non-small cell lung cancer models. ATNM-400 is a first-in-class Actinium-225 antibody radioconjugate targeting HER3, aiming to expand targeted radiotherapy applications across various solid tumors.